In collaboration with the University of Massachusetts Medical School (UMMS) and Auburn University (AU), Lysogene is developing IND - supporting preclinical studies using
AAV gene therapy technology to translate the initial proof of concept into a viable drug development program to the benefit of patients in urgent need.